ReproNovo
Latest round
- Series A
Last raised
- May 2025
Total raised
- $64M
Investors
- 5
About ReproNovo
Based in Switzerland, ReproNovo ApS engages in developing innovative therapeutic solutions aimed at enhancing reproductive medicine and women's health, particularly addressing infertility challenges. ReproNovo ApS focuses on advanced therapeutic approaches within reproductive health. Founded in 2021 in Lausanne, Switzerland. ReproNovo specializes in innovative therapeutic solutions focused on improving reproductive medicine and women's health. The company’s core product offerings include treatments for male and female infertility, as well as pioneering options for conditions such as adenomyosis, a complex uterine disorder. These products are designed to enhance success rates in assisted reproductive technologies, addressing critical gaps in the current treatment landscape. ReproNovo's solutions are aimed at individuals facing infertility challenges, with a significant focus on providing effective alternatives where traditional treatments are limited or non-existent. The company's products are marketed primarily in Europe, with ongoing efforts to expand their reach in international markets, thereby serving a diverse client base of healthcare providers and patients seeking reproductive health solutions. The company engages in business-to-business transactions, ensuring that its innovative therapies reach clinics and fertility specialists who utilize these products in patient treatments. Revenue streams are structured around licensing agreements and distribution partnerships, allowing healthcare providers to integrate ReproNovo's therapies into their offerings. The company’s flagship services are expected to be part of comprehensive treatment packages that healthcare providers offer to patients seeking assistance with infertility and related conditions. The company aims to expand into new markets, specifically targeting broader European markets and other international regions, to enhance access to their innovative reproductive health solutions. Upcoming product launches are expected to focus on advanced treatments for infertility and related conditions, although specific release dates have yet to be disclosed.
Who invested in ReproNovo
5 investors across 1 round
See all investors in ReproNovo
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
May 21, 2025
Amount
$64M
Investors
Questions about ReproNovo
Who invested in ReproNovo?
ReproNovo has 5 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has ReproNovo raised?
ReproNovo has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did ReproNovo last raise money?
ReproNovo's most recent round on record is a Series A, in May 2025.
What does ReproNovo do?
Based in Switzerland, ReproNovo ApS engages in developing innovative therapeutic solutions aimed at enhancing reproductive medicine and women's health, particularly addressing infertility challenges.
Where is ReproNovo headquartered?
ReproNovo is headquartered in Lausanne, Switzerland.
Which VCs invest in companies like ReproNovo?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at ReproNovo's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like ReproNovo? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.